Nippon Shinyaku Co., Ltd. (NPPNY)
Nippon Shinyaku Co., Ltd. operates in the Medical - Pharmaceuticals industry of the Healthcare sector, headquartered in Kyoto, KY, JP. The stock last traded at $6.11, up 0.00% on the session, giving a market capitalisation of $1.65B. On trailing twelve-month figures it carries a trailing P/E of 7.69, a net margin of 17.5%. Its beta of -0.32 implies it has historically moved less than the broad market.
Nippon Shinyaku Co., Ltd. manufactures and sells pharmaceuticals and foodstuffs in Japan and internationally. The company operates through Pharmaceuticals and Functional Food Business segments. It offers drugs in the fields of urology, hematology, intractable and rare diseases, gynecology, and other diseases; health food ingredients, preservatives, protein preparations, and supplements. The company in the Strategic Partnership with Nippon Shinyaku to develop ATSN-10 that is in Phase I/II of clinical trials for the treatment of GUCY2D-mutant Leber congenital amaurosis; and RGX-121 for the treatment of mucopolysaccharidosis. Nippon Shinyaku Co., Ltd. was founded in 1911 and is headquartered in Kyoto, Japan.
Nippon Shinyaku Co., Ltd. is most often compared with the following Healthcare names: